Effectiveness and safety of combined therapy versus monotherapy based on immune checkpoint inhibitors and/or targeted drugs as salvage treatment for advanced urothelial carcinoma: a systematic review and meta-analysis

被引:1
作者
Wei, Lichao [1 ]
Gao, Liang [1 ]
Hu, Zili [1 ]
Liu, Chuan [1 ]
机构
[1] Chongqing Med Univ, Dept Urol, Affiliated Hosp 2, 74 Linjiang Rd, Chongqing 400010, Peoples R China
关键词
Urothelial carcinoma (UC); salvage therapy; novel agents; combined therapy; monotherapy; PHASE-II TRIAL; OPEN-LABEL; 2ND-LINE TREATMENT; SINGLE-ARM; G-CSF; CANCER; MULTICENTER; PACLITAXEL; CHEMOTHERAPY; EVEROLIMUS;
D O I
10.21037/tcr-20-3354
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The standard salvage regimen for the patients with advanced urothelial carcinoma (UC) is uncertain, although lots of novel agents are recommended, including immune checkpoint inhibitors (ICIs) and targeted drugs (TDs). We aimed to compare the effectiveness and safety of combined therapy of novel agents (CNA) and monotherapy of novel agents (MNA) as salvage therapy for advanced UC. Methods: Studies exploring CNA and/or MNA for advanced UC in second-line setting were searched from PubMed, Embase, Cochrane Library, and Web of Science. The data of objective response rate (ORR), disease control rate (DCR), median progression-free survival (PFS), median overall survival (OS), and grade 3-4 adverse effects rate (grade 3-4 AEs%) were pooled for analyses. Cochrane risk of bias tool was applied for the quality judgment of randomized controlled studies (RCTs). Results: Forty-one arms from 37 studies including 4,691 patients were included. Significant differences were presented in pooled ORR (22.9% versus 12.2%, OR=1.88, P<0.001) and DCR (62.7% versus 37.5%, OR=2.53, P<0.001) between CNA and MNA groups. The pooled median PFS was 3.66 months in CNA group versus 2.16 months in MNA group (WMD=1.50, P=0.028). No significant difference in pooled median OS was found between two groups (7.93 versus 7.50 months, WMD=0.43, P=0.449). 63.7% versus 25.4% of pooled grade 3-4 AEs% could be seen in CNA and MNA groups (OR=3.52, P<0.001). Additionally, the pooled results of PFS-6m and OS-6m in CNA group demonstrated significant advantages over MNA group (31.5% versus 28.7%, OR=1.31, P=0.049; 66.0% versus 56.7%, OR=1.34, P=0.029, respectively). In the subgroup analysis of CNA, use of ICIs, the positive expression of PD-L1 and ECOG-PS=0 were significantly associated with superior clinical outcomes (P<0.05). Discussion: For advanced UC patients after first line agents, CNA had potential benefits than MNA in terms of ORR, DCR, median PFS, PFS-6m and OS-6m. However, CNA was associated with a significantly higher grade 3-4 AEs%. Furthermore, potential advantages were presented in CNA patients with ICIs usage, positive PD-L1 expression and ECOG-PS=0.
引用
收藏
页码:2091 / +
页数:22
相关论文
共 54 条
[21]   Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis [J].
Necchi, Andrea ;
Pond, Gregory R. ;
Raggi, Daniele ;
Giannatempo, Patrizia ;
Vogelzang, Nicholas J. ;
Grivas, Petros ;
Galsky, Matthew D. ;
Bellmunt, Joaquim ;
Sonpavde, Guru .
CLINICAL GENITOURINARY CANCER, 2017, 15 (01) :23-30
[22]   Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial [J].
Necchi, Andrea ;
Mariani, Luigi ;
Zaffaroni, Nadia ;
Schwartz, Lawrence H. ;
Giannatempo, Patrizia ;
Crippa, Flavio ;
Morosi, Carlo ;
Lanocita, Rodolfo ;
Sava, Teodoro ;
Ortega, Cinzia ;
Messina, Caterina ;
Sacco, Cosimo ;
Pennati, Marzia ;
Daidone, Maria G. ;
Nicolai, Nicola ;
De Braud, Filippo ;
Gianni, Alessandro M. ;
Salvioni, Roberto .
LANCET ONCOLOGY, 2012, 13 (08) :810-816
[23]   Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09) [J].
Niegisch, Guenter ;
Retz, Margitta ;
Thalgott, Mark ;
Balabanov, Stefan ;
Honecker, Friedemann ;
Ohlmann, Carsten Henning ;
Stoeckle, Michael ;
Boegemann, Martin ;
vom Dorp, Frank ;
Gschwend, Juergen ;
Hartmann, Arndt ;
Ohmann, Christian ;
Albers, Peter .
ONCOLOGY, 2015, 89 (02) :70-78
[24]   Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer [J].
Noronha, Vanita ;
Patil, Vijay Maruti ;
Joshi, Amit ;
Menon, Nandini ;
Chougule, Anuradha ;
Mahajan, Abhishek ;
Janu, Amit ;
Purandare, Nilendu ;
Kumar, Rajiv ;
More, Sucheta ;
Goud, Supriya ;
Kadam, Nandkumar ;
Daware, Nilesh ;
Bhattacharjee, Atanu ;
Shah, Srushti ;
Yadav, Akanksha ;
Trivedi, Vaishakhi ;
Behel, Vichitra ;
Dutt, Amit ;
Banavali, Shripad Dinanath ;
Prabhash, Kumar .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) :124-+
[25]   Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses [J].
Ohyama, Chikara ;
Kojima, Takahiro ;
Kondo, Tsunenori ;
Naya, Yoshio ;
Inoue, Takamitsu ;
Tomita, Yoshihiko ;
Eto, Masatoshi ;
Hisasue, Shinichi ;
Uemura, Hirotsugu ;
Obara, Wataru ;
Kikuchi, Eiji ;
Sharma, Padmanee ;
Galsky, Matthew D. ;
Siefker-Radtke, Arlene ;
Grossfeld, Gary ;
Collette, Sandra ;
Gooden, Kyna ;
Kimura, Go .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (09) :1089-1098
[26]   Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States [J].
Pal, Sumanta Kumar ;
Hoffman-Censits, Jean ;
Zheng, Hanzhe ;
Kaiser, Constanze ;
Tayama, Darren ;
Bellmunt, Joaquim .
EUROPEAN UROLOGY, 2018, 73 (05) :800-806
[27]   Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study [J].
Parikh, Mamta ;
Pan, Chong-Xian ;
Beckett, Laurel A. ;
Li, Yueju ;
Robles, Daniel A. ;
Aujla, Pawandeep K. ;
Lara, Primo N., Jr. .
CLINICAL GENITOURINARY CANCER, 2018, 16 (06) :421-+
[28]   Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial [J].
Patel, Manish R. ;
Ellerton, John ;
Infante, Jeffrey R. ;
Agrawal, Manish ;
Gordon, Michael ;
Aljumaily, Raid ;
Britten, Carolyn D. ;
Dirix, Luc ;
Lee, Keun-Wook ;
Taylor, Mathew ;
Schoffski, Patrick ;
Wang, Ding ;
Ravaud, Alain ;
Gelb, Arnold B. ;
Xiong, Junyuan ;
Rosen, Galit ;
Gulley, James L. ;
Apolo, Andrea B. .
LANCET ONCOLOGY, 2018, 19 (01) :51-64
[29]   Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial [J].
Petrylak, Daniel P. ;
de Wit, Ronald ;
Chi, Kim N. ;
Drakaki, Alexandra ;
Sternberg, Cora N. ;
Nishiyama, Hiroyuki ;
Castellano, Daniel ;
Hussain, Syed A. ;
Flechon, Aude ;
Bamias, Aristotelis ;
Yu, Evan Y. ;
van der Heijden, Michiel S. ;
Matsubara, Nobuaki ;
Alekseev, Boris ;
Necchi, Andrea ;
Geczi, Lajos ;
Ou, Yen-Chuan ;
Coskun, Hasan Senol ;
Su, Wen-Pin ;
Bedke, Jens ;
Gakis, Georgios ;
Percent, Ivor J. ;
Lee, Jae-Lyun ;
Tucci, Marcello ;
Semenov, Andrey ;
Laestadius, Fredrik ;
Peer, Avivit ;
Tortora, Giampaolo ;
Safina, Sufia ;
Garcia del Muro, Xavier ;
Rodriguez-Vida, Alejo ;
Cicin, Irfan ;
Harputluoglu, Hakan ;
Tagawa, Scott T. ;
Vaishampayan, Ulka ;
Aragon-Ching, Jeanny B. ;
Hamid, Oday ;
Liepa, Astra M. ;
Wijayawardana, Sameera ;
Russo, Francesca ;
Walgren, Richard A. ;
Zimmermann, Annamaria H. ;
Hozak, Rebecca R. ;
Bell-McGuinn, Katherine M. ;
Powles, Thomas .
LANCET ONCOLOGY, 2020, 21 (01) :105-120
[30]   Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer Long-term Outcomes From a Phase 1 Study [J].
Petrylak, Daniel P. ;
Powles, Thomas ;
Bellmunt, Joaquim ;
Braiteh, Fadi ;
Luriot, Yohann ;
Murales-Barrera, Rafael ;
Burris, Howard A. ;
Kim, Joseph W. ;
Ding, Beiying ;
Kaiser, Constanze ;
Fasso, Marcella ;
O'Hear, Carol ;
Vogelzang, Nicholas J. .
JAMA ONCOLOGY, 2018, 4 (04) :537-544